|
Sep 30
|
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
|
|
Sep 27
|
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
|
|
Aug 8
|
Aquestive Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
|
Aug 6
|
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Aug 6
|
Aquestive Therapeutics: Q2 Earnings Snapshot
|
|
Jul 30
|
Institutions profited after Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) market cap rose US$72m last week but retail investors profited the most
|
|
Jul 25
|
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
|
|
Jul 23
|
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
|
|
Jun 25
|
Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
|
|
Jun 25
|
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
|
|
Jun 19
|
Investors in Aquestive Therapeutics (NASDAQ:AQST) have unfortunately lost 36% over the last five years
|
|
Jun 18
|
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
|
|
May 9
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
|
|
May 9
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
|
|
May 9
|
Aquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 7
|
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
|
|
May 7
|
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
|